Glaucoma Surgery Devices Market

Global Glaucoma Surgery Devices Market Size (2024 to 2029)

The worldwide glaucoma surgery devices market is estimated to be growing at a CAGR of 31.2% from 2024 to 2029 and worth USD 6250 million by 2029 from USD 1607 million in 2024.

Glaucoma is an eye disease that is now the most significant cause of blindness globally. Glaucoma is caused by a blockage in eye fluid drainage, increasing intraocular pressure. As a result of the increased eye pressure, damage to the eyesight develops. Eye drops, tablets, laser surgery, conventional surgery, or a combination of these procedures can be used to treat glaucoma. Laser- and non-laser-based implants, drainage devices, and other glaucoma surgery technologies lower intraocular pressure in the eye by emptying excess collected eye fluid. Glaucoma surgery devices are predicted to gain traction since they are crucial in treating glaucoma.

MARKET DRIVERS

The continuous rise in the prevalence of glaucoma, the growing aging population, and the rising use of surgical glaucoma therapies are majorly boosting the growth of the glaucoma surgery devices market. Glaucoma is becoming more common, the senior population is growing, and surgical therapies for glaucoma are becoming more popular. Furthermore, favorable reimbursement policies, increased government initiatives, and improvements in healthcare in emerging nations are projected to drive the market for glaucoma surgery devices. In addition, the increased number of glaucoma care efforts being carried out by the government and various non-governmental organizations is projected to impact advanced technology adoption positively. These groups provide eye exams and mass surgery camps, raise awareness, and fund surgical methods and technology. As a result of these activities, the number of undetected instances of glaucoma has decreased, increasing the demand for glaucoma treatment techniques and technologies.

In addition, the global glaucoma surgery devices market is projected to have various opportunities as the industry transitions from glaucoma drugs to minimally invasive glaucoma operations. The increased need for minimally invasive glaucoma surgery (MIGS) treatments is expected to fuel the demand for better glaucoma surgery devices during the forecast period. Because of advantages such as cheaper costs, faster recovery periods, and shorter operation durations, MIGS techniques and devices are becoming increasingly prevalent. These operations also have a lower risk of post-operative complications such as hypotony. The primary purpose of these devices is to maintain or reduce intraocular pressure (IOP). The demand for successful glaucoma surgical technologies is continuously increasing due to faster glaucoma treatment to avert visual loss. The high prevalence of glaucoma around the world and an increase in the use of glaucoma operations are two other significant drivers expected to drive the worldwide glaucoma surgery devices market forward during the forecast period.

MARKET RESTRAINTS

However, the global glaucoma surgery devices market is forecasted to be hampered by a lack of awareness of glaucoma and the devices connected with it in some developing and undeveloped economies. In addition, inadequate reimbursement is projected to limit the use of MIGS devices and hamper the market's growth in the forecasted period. Furthermore, the high expense of glaucoma surgical treatments, a scarcity of competent specialists, and an increase in postoperative problems are a few other factors that could slow the market growth during the forecast period.

Impact of COVID-19 on the Global Glaucoma Surgery Devices Market

The COVID-19 pandemic is a global public health crisis expected to negatively influence the glaucoma surgery devices market. The COVID-19 pandemic and associated economic slump have significantly affected global demand for devices utilized in elective surgeries and therapies. Before the COVID-19 pandemic, the iStent inject, followed by XEN and Preserflo, was the most routinely used MIGS procedure in minimally invasive glaucoma surgery (MIGS). Even though trabeculectomy is still the most common established glaucoma surgery, it is being performed less frequently during the COVID-19 pandemic because of the reduced number of postoperative visits and treatments. However, the global glaucoma surgery devices market is expected to regain momentum very soon and perform well during the forecast period.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Glaucoma Surgery Devices Market Analysis By Product

Based on the product, the glaucoma drainage devices segment dominated the global glaucoma surgery devices market in 2023 and are predicted to grow at the quickest CAGR throughout the forecast period. In addition, cataract surgery and glaucoma surgery are frequently performed together. Therefore, the high number of cataract procedures is likely to affect segment growth positively.

Global Glaucoma Surgery Devices Market Analysis By Surgery

In 2023, the traditional glaucoma surgery segment had most of the share in the global glaucoma surgery devices market. However, more extended hospital stays, the availability of other advanced surgical techniques and devices, and the increasing risk of postoperative problems like leakage, hypotony, choroidal effusion, and hyphema are just a few of the issues prompting patients and surgeons to seek alternatives. On the other hand, traditional surgery is still the primary choice in emerging countries, where private actors dominate the healthcare service industry.

Global Glaucoma Surgery Devices Market Analysis By End-User

In 2023, the eye hospital segment accounted for the largest share of the market, and it is expected to grow at a healthy rate over the forecast period. The segment's growth is expected to be aided by a large patient base, the availability of highly skilled medical professionals, and advanced surgical devices.

REGIONAL ANALYSIS

Because of the increased prevalence of glaucoma, the expanding elderly population, rising awareness, favorable reimbursement policies, and the presence of several key competitors, North America is likely to hold a substantial share of the worldwide glaucoma surgery devices market. Furthermore, glaucoma is more common among the growing number of older populations in the United States. Furthermore, rising healthcare spending and well-established infrastructure contribute to the overall regional market's growth.

Europe had the second-largest proportion in the global glaucoma surgery devices market in 2023. In terms of glaucoma surgery, the region has a dynamic reimbursement paradigm, with certain nations having adequate coverage for current surgical techniques and methods. In contrast, others must rely on trabeculectomy despite the availability of more advanced choices. As a result, the number of glaucoma procedures conducted annually in European countries like Germany, France, and Russia is the greatest in the world.

Japan held the largest share of the Asia-Pacific glaucoma surgery devices market, which is expected to remain during the forecast period. This is due to a rise in demand for ophthalmic devices and the easy availability of glaucoma surgery instruments from companies in the country, such as Topcon Corporation and Hoya Corporation. On the other hand, because of the rising incidence of glaucoma and increased government activities to raise awareness about the prevention of blindness and treatment of glaucoma using micro-invasive surgical methods, China is dominating the Asia-Pacific market.

KEY MARKET PARTICIPANTS

Abbott Laboratories, Glaukos Corporation, Alcon, Inc., Ziemer Ophthalmic Systems AG ASICO, Katalyst Surgical, Nidek Co., Carl Zeiss Meditec AG, Iridex Corporation, Ltd., Ellex Medical Lasers Ltd., Johnson & Johnson, Bausch & Lomb, Inc., Topcon Corporation, HAAG-Streit Holding AG, Essilor International S.A., Hoya Corporation and Sonomed Escalon are a few of the notable companies operating in the global glaucoma surgery devices market profiled in this report.

RECENT HAPPENINGS IN THIS MARKET

• Glaukos, an ocular medical technology and pharmaceutical company, and Avedro, a leading hybrid ophthalmic medical technology company, signed a definitive deal in August 2019 to purchase Avedro.
• MicroSurgical Technology (MST) developed the MST 19-gauge Ahmed Micro-Stent Cutter in July 2019 in collaboration with glaucoma and cataract specialist Ike Ahmed, MD.

DETAILED SEGMENTATION OF THE GLOBAL GLAUCOMA SURGERY DEVICES INCLUDED IN THIS REPORT

This research report on the global glaucoma surgery devices market has been segmented and sub-segmented based on the product, surgery method, end-user, and region.

By Product

• Glaucoma Laser Devices
• Glaucoma Drainage Devices
• Implants & Stents

By Surgery

• Minimally Invasive Glaucoma Surgeries
• Traditional glaucoma surgery

By End-User

• Eye Hospitals
• Ophthalmology Clinics
• Outpatient Surgical Centers